{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:45:54Z","timestamp":1792691154963,"version":"4.5.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jiph.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T12:58:29Z","timestamp":1561121909000},"page":"149-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9637-6365","authenticated-orcid":false,"given":"Braira","family":"Wahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jiph.2019.06.004_bib0005","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/hep.23461","article-title":"Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial\/ethnic differences, and viral interactions","volume":"51","author":"Bini","year":"2010","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.jiph.2019.06.004_bib0010","doi-asserted-by":"crossref","first-page":"589","DOI":"10.12998\/wjcc.v6.i13.589","article-title":"Update on global epidemiology of viral hepatitis and preventive strategies","volume":"6","author":"Jefferies","year":"2018","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.jiph.2019.06.004_bib0015","first-page":"1","article-title":"Hepatitis review on current and future scenario","volume":"3","author":"Pallavi","year":"2017","journal-title":"J In Silico In Vitro Pharmacol"},{"issue":"s1","key":"10.1016\/j.jiph.2019.06.004_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1478-3231.2011.02703.x","article-title":"2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines","volume":"32","author":"Calvaruso","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jiph.2019.06.004_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcv.2016.02.026","article-title":"Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge","volume":"78","author":"De Monte","year":"2016","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.jiph.2019.06.004_bib0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13256-015-0630-8","article-title":"Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report","volume":"9","author":"Ende","year":"2015","journal-title":"J Med Case Rep"},{"issue":"3","key":"10.1016\/j.jiph.2019.06.004_bib0035","first-page":"254","article-title":"Hepatitis E virus coinfection with hepatotropic viruses in Egyptian children","volume":"41","author":"Zaki","year":"2008","journal-title":"J Microbiol Immunol Infect"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034119301923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034119301923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:05:08Z","timestamp":1761750308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034119301923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1876034119301923"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2019.06.004","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}